Cidofovir
| Clinical data | |
|---|---|
| Trade names | Vistide |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | complete |
| Protein binding | <6% |
| Elimination half-life | 2.6 hours (active metabolites: 15–65 hours) |
| Excretion | renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid.[2] |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.166.433 |
| Chemical and physical data | |
| Formula | C8H14N3O6P |
| Molar mass | 279.189 g·mol−1 |
| 3D model (JSmol) | |
| Specific rotation | -97.3 |
| Melting point | 260 °C (500 °F) |
SMILES
| |
InChI
| |
| (verify) | |
Cidofovir, brand name Vistide, is a topical or injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS.[3][4]
Cidofovir was approved for medical use in 1996.[5]
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ Cundy, Kenneth C. "Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir." Clinical Pharmacokinetics 36.2 (1999): 127–143.
- ^ Cite error: The named reference
MSRwas invoked but never defined (see the help page). - ^ Cite error: The named reference
TGAwas invoked but never defined (see the help page). - ^ Long SS, Prober CG, Fischer M (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029.